Table 2 Odds ratios and 95% CI for risk of Barrett’s oesophagus associated with serum leptin and serum adiponectin concentration: pilot study
ControlsBarrett’s oesophagus casesOR‡ (95% CI)
Serum leptin category*
    Q11661.0 (Ref)
    Q217173.0 (0.9 to 9.6)
    Q316102.5 (0.4 to 13.8)
    Q418184.6 (0.6 to 33. 4)
    ptrend0.15
Serum adiponectin category†
    Q116181.0 (Ref)
    Q21790.5 (0.2 to 1.4)
    Q316110.6 (0.2 to 1.9)
    Q418130.7 (0 to 2.1)
    ptrend0.61

  • OR, Odds ratio.

  • *Cutpoints for serum leptin (ng/ml) in the pilot study: men Q1 0–3.8; Q2 3.9–7.5, Q3 7.6–18.6; Q4 ⩾18.6; women Q1 0–8.6; Q2 8.7–23.6, Q3 23.7–35.8; Q4 ⩾35.8.

  • †Cutpoints for serum adiponectin (μg/ml) in the pilot study: men Q1 0–6.87; Q2 6.88–8.69 5, Q3 8.70–13.62; Q4 ⩾13.63; women Q1 0–8.18; Q2 8.19–11.22, Q3 11.23–14.30; Q4 ⩾14.31.

  • ‡Odds ratio adjusted for age, sex and current body mass index.